Telix Pharmaceuticals (TLX) said Tuesday that it has selected Cardinal Health (CAH) as one of its commercial radiopharmaceutical distributors to supply finished unit doses of Gozellix for the treatment of prostate cancer in the US.
The company said it wants to enable availability across a wide range of US locations following the recent US Food and Drug Administration approval of Gozellix and in preparation for its commercial launch during the first half of 2025.
Cardinal Health will operate as a strategic radiopharmacy distributor for Gozellix alongside Telix's in-house radiopharmacy network, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。